Fate Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
FATE Nasdaq 2834 www.fatetherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Feb 3rd, 2026 2:05 pm
Companies Like Fate Therapeutics (NASDAQ:FATE) Could Be Quite Risky - Dec 21st, 2025 7:24 am
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs - Dec 8th, 2025 6:00 am
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference - Nov 25th, 2025 6:00 am
Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates - Nov 13th, 2025 7:40 am
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates - Nov 13th, 2025 6:30 am
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - Nov 4th, 2025 8:00 am
Incyte (INCY) Tops Q3 Earnings and Revenue Estimates - Oct 28th, 2025 6:15 am
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy - Oct 26th, 2025 9:30 am
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer - Oct 14th, 2025 6:00 am
Fate Therapeutics, Inc. (NASDAQ:FATE) institutional owners may be pleased with recent gains after 62% loss over the past year - Oct 4th, 2025 8:16 am
Fate Therapeutics to Present at Upcoming Investor Conferences - Aug 25th, 2025 6:00 am
[Latest] Global Induced Pluripotent Stem Cells Production Market Size/Share Worth USD 4.34 Billion by 2034 at a 9.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT) - Aug 21st, 2025 1:30 pm
Fate Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Aug 14th, 2025 4:16 am
Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates - Aug 12th, 2025 3:15 pm
Fate Therapeutics: Q2 Earnings Snapshot - Aug 12th, 2025 2:30 pm
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates - Aug 12th, 2025 2:01 pm
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates - Aug 11th, 2025 4:55 pm
Health Catalyst (HCAT) Q2 Earnings and Revenues Beat Estimates - Aug 7th, 2025 4:25 pm
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates - Aug 6th, 2025 5:45 am